<DOC>
	<DOC>NCT01437540</DOC>
	<brief_summary>The purpose of this study is to assess the long-term safety and tolerability of inhaled aclidinium bromide/formoterol in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD).</brief_summary>
	<brief_title>Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Current or former cigarette smokers with a cigarette smoking history of at least 10 packyears A diagnosis of stable moderate to severe COPD and stable airway obstruction as defined by the Global Initiative for Chronic Obstructive Lung Disease guidelines and stable airway obstruction. Patients who have been hospitalized for an acute COPD exacerbation within three months prior to Visit 1 Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the six weeks before Visit 1. Patients with any clinically significant respiratory conditions other than COPD Clinical history that suggests that the patient has asthma as opposed to COPD Chronic use of oxygen therapy â‰¥ 15 hours/day Patients with clinically significant cardiovascular conditions Patients with uncontrolled infection that may place the patient at risk resulting from human immunodeficiency virus (HIV), active hepatitis and/or patients with diagnosed active tuberculosis Patients with a history of hypersensitivity reaction to inhaled anticholinergics, Patients with Stage II hypertension, defined as systolic pressure of 160 and above, and/or diastolic pressure of 100 and above Current diagnosis of cancer other than basal or squamous cell skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Chronic Bronchitis</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Airflow Obstruction, Chronic</keyword>
	<keyword>Chronic Airflow Obstruction</keyword>
	<keyword>Chronic Obstructive Airway Disease</keyword>
	<keyword>Chronic Obstructive Lung Disease</keyword>
</DOC>